Clinical Trials Logo

Peritoneal Metastasis clinical trials

View clinical trials related to Peritoneal Metastasis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05544253 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC

Start date: October 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Hepatocellular carcinoma (HCC) is featured by the spontaneously rupture when suffering severe cirrhosis and intratumoral overpressure. It is a fatal complication with an acute mortality. Importantly, it is served as an independent risk factor for peritoneal metastasis (PM) of HCC with poor prognosis. The systematic agents effective to extrahepatic lesions confers modest efficacy towards PM. HIPEC, as a novel strategy, has been proved by overwhelming studies that it is effective to peritoneal malignant tumors. However, there is absence of prospective study of HIPEC efficacy towards HCC.

NCT ID: NCT02779608 Recruiting - Stomach Neoplasms Clinical Trials

The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites

Start date: January 20, 2017
Phase: Phase 2
Study type: Interventional

This is a clinical Study to evaluate the effect, survival benefit and safety of intraperitoneal docetaxel combined with oral S-1 for advanced gastric cancer with malignant ascites.

NCT ID: NCT02591667 Recruiting - Colorectal Cancer Clinical Trials

Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer

CARCINOSIS
Start date: March 2016
Phase: Phase 2
Study type: Interventional

There is a paucity of data on the histopathological response of peritoneal tumor deposits from colorectal cancer to neoadjuvant chemotherapy. Particularly, no prospective assessment of chemotherapy-associated histopathological response within the peritoneum has been performed so far. Therefore, there is an urgent need to conduct a clinical trial aimed at prospectively assessing the histopathological response within the peritoneum in patients with peritoneal metastasis from colorectal cancer. Recently, Loupakis et al. reported that the triplet regimen of 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) in combination with bevacizumab significantly improved median progression-free survival in metastatic colorectal cancer patients from 9.7 to 12.1 months as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab. In view of these data, it is likely that FOLFOXIRI + bevacizumab will also lead to a significant improvement of the histopathological response within the peritoneum of patients with peritoneal metastasis from colorectal cancer (pcCRC) as compared with previous standard chemotherapy. The investigators hypothesize that FOLFOXIRI + bevacizumab will induce a pCR or major response in peritoneal tumor deposits in >30% of patients (taking the response rate to FOLFOX- or FOLFIRI-based neoadjuvant chemotherapy from the published literature as a reference).